Research
Hormonal
GLP-1 receptor agonists (semaglutide, tirzepatide) produce significant weight loss (up to 25%) and improve cardiometabolic health, including cardiovascular and renal outcomes.
GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss and heart health. They work by mimicking hormones that control hunger and metabolism. Discuss these options with your doctor if lifestyle changes alone haven't worked.
StrongSupportsHIGH confidence
Tirzepatide is a dual GIP and GLP-1 RA... These trials have showed a mean weight loss of 12.8–25.3%... Semaglutide was approved by the FDA in 2024 as the first GLP-1RA to reduce CVD mortality in individuals with overweight and obesity regardless of diabetes status
Why this rating
Based on multiple RCTs (STEP, SURMOUNT, SELECT) and FDA approvals.
Source
Obesity as a Chronic Disease: A Narrative Review of Evolving Definitions, Management Strategies, and Cardiometabolic Prioritization
Vidhi Singh et al. · Advances in Therapy · 2025
DOI 10.1007/s12325-025-03352-y
narrative_reviewCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity is a chronic disease driven by dysfunctional adipose tissue and dysregulated energy homeostasis, requiring medical treatment rather than solely lifestyle changes.Strong
- BMI is an inadequate measure of obesity because it does not distinguish between lean muscle mass and adipose tissue, leading to misclassification of metabolic health.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →